2010 AnnuAl REpoRT - Ciberdem

IREVAS: 2009-2010
Coordinator: Manuel Benito
CIBERDEM groups: R Gomis, M Benito, D Burks
Di@bet.es Study: 1st epidemiological study of the
prevalence of type 2 diabetes in Spain
Coordinator: F Soriguer
CIBERDEM groups: R Gomis, F Soriguer, R Carmena, L
Castaño, M Serrano Ríos, J Vendrell
CIBERDEM Biobank
Coordinator: A Novials
CIBERDEM Biobank Nodes: R Gomis, A Novials, J Vendrell,
L Masana, L Castaño, M Serrano Ríos, F Soriguer, R
Carmena, F Blanco Vaca
Clinical trials
Trial, randomized, double-blind, placebo controlled and
peer-group to assess the efficacy and safety of Linagliptin
(5 mg) orally administered once a day for more than 52
weeks in type 2 diabetes patients combined with insulin as
base treatment. Phase III
Boehringer Ingelheim: 2009-in progress
Researcher: Ramon Gomis
Multicenter trial, international, randomized and 2x2 factorial
to assess the effects of Lantus (glargin insulin) compared to
the standard treatment with omega 3 fatty acids compared
to placebo, in the decrease in cardiovascular morbility and
mortality in high risk patients with altered fasting glucose
(AFG), decrease in glucose tolerance (TGD) or type 2
diabetes in initial stages. Phase IV
Sanofi Aventis: 2004- in progress
Steering Committee Member: Ramon Gomis
Observational follow-up study of patients previously
attended in exubera controlled clinical trials. Phase IV
Pfizer: 2009- in progress
Researcher: Ramon Gomis
AstraZeneca Farmacéutica: 2008-2010
Researcher: Ramon Gomis
Glucose Control in Type 2 Diabetes Mellitus with insulin
pump therapy. OpT2mise Project
IP for the center and Steering Committee Member: Ignacio
Conget
Sensing With Insulin Pump Therapy to Control HbA1c.
SWITCH study
IP for the center and Steering Committee Member: Ignacio
Conget
Proyecto REWIND Reducing CV Events by a Weekly INcretin
in Diabetes
2010-in progress
Coordinator and Steering Committee Member: Ignacio
Conget
PhD theses
Efecte hipotalàmic del tungstat de sodi i la seva relació
amb la via de la leptina: una posible teràpia antiobesitat
Author: Marta Amigó Correig
Thesis advisors: Ramon Gomis, M Carmen Carmona
University: Universitat de Barcelona
Thesis defense date: January 20, 2010
Bases moleculares del efecto del tungstato de sodio sobre
la plasticidad pancreática y Tmem27
Author: Jordi Altirriba Gutiérrez
Thesis advisor: Ramon Gomis
University: Universitat de Barcelona
Thesis defense date: July 27, 2010
Plasticitat de la cèl·lula beta en l’obesitat
Author: Núria Palau Balañá
Thesis advisor: Ramon Gomis
University: Universitat de Barcelona
Thesis defense date: July 29, 2010 ■
Study of 24 weeks, international, randomized, peer-group,
double-blind and placebo controlled with an extended period
of 24 weeks to assess efficacy and safety of dapaglifocin
added to treatment of type 2 diabetes mellitus patients with
poor control of glycaemia with insulin. Phase III
Astra Zeneca : 2009- in progress
Researcher: Ramon Gomis
Study of 24 weeks and 28 weeks of follow-up, multicenter,
randomized, double-blind, age stratified, and placebo
controlled to evaluate the efficacy and safety of
dapagliflozin 10mg once a day, in DM2 patients with
history of cardiovascular disease, hypertensive and with
poor control of glycaemia with their usual treatment.
Phase III
114 CibeRdem